George Johnson - uventia

George Johnson

George Johnson

George Johnson

Associate Professor

Swansea-University

George Johnson is an Associate Professor at Swansea University, Wales UK. He continues to work with the in vitro Toxicology group in the Institute of Life Science. He is co-chair of the Health and Environmental Sciences Institute (HESI) Genetic Toxicology Technical Committee (GTTC) and co-chair of the quantitative workgroup, working on projects including nitrosamine impurities.
George has worked on projects with US-FDA-NCTR, BfArM, European Medicines Agency (EMA), Health Canada, RIVM-Netherlands, Food Standards Agency along with the pharmaceutical industry and many other companies.
George was President of the EEMGS society in 2021-2023. George has consulted with clients including the pharmaceutical, food additive, fragrances, agrochemical and chemical industries. A major aspect of many of these projects has been the derivation of point of departure metrics for use in human health risk assessments.

SPEAKED ABOUT:
Genotoxic-Impurities-Nitrosamines-Beyond
December 4, 2024
Meeting with subject matter experts to evaluate different points of view on how to solve the problems associated with mutagenic impurities. Recording of 2 days event sessions [13 video sessions].
Expired

DAY 2: December 5th, 2024

SESSION: Using relative potency of mutation and cancer data, to derive AI’s for Nitrosamines

◆  Using benchmark dose (BMD) analysis to compare potencies.

◆  Relative potency between mutation and cancer for different nitrosamines.

◆  Using relative potency to calculate acceptable intakes from in vivo mutation data.

3rd Annual Genotoxic Impurities Nitrosamines & Beyond
November 30, 2023
Learn the best techniques and cutting-edge methods for reducing genotoxic and elemental impurities. Recording of 2 days event sessions [17 video sessions].
Expired

DAY 1: November 30th, 2023

SESSION: Using genetic toxicity data to support risk assessment of nitrosamines

◆  In vivo mutation and cancer potency.

◆  Using in vivo mutation data to support potency categorisation.

◆  Next steps and upcoming data sets and approaches.

Speaker Details
Speaker Details